Wolfgang Teschner

This inventor holds 35 USPTO granted patents and 8 published patent applications and 13 EPO patents, primarily in Immunoglobulin Preparation. Top assignees: Baxalta Gmbh, Baxter Healthcare Sa, Baxter International Inc.. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wolfgang Teschner. Retrieved from https://idiyas.com/inventor/wolfgang-teschner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 35 (Patent Applications = 8)

% Patents Active = 100.0

EPO Patents = 13 (Patent Applications = 21)

Average Co-Inventor Count = 6.1

ph-index = 8

Forward Citations = 248(Granted Patents)

Company Filing History:

Baxter International Inc.

patents

4. 7 out of 1,226

Takeda Pharmaceutical Company Limited

patents

5. 1 out of 67

Baxter Aktiengesellschaft

patents

6. 1 out of 83

Immuno Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

Immunoglobulin Preparation

Human Plasma

Serine Proteases

Factor H

Aqueous Formulation

Thromboembolic Potential

Hyaluronidase

Plasma Protein

Natural IgGs

Concentration

Yield Improvement

Membrane Adsorption

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630613 - Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use (2026-05-19),

2. 12623164 - Filter press adapter (2026-05-12),

3. 12545703 - Method to produce an immunoglobulin preparation with improved yield (2026-02-10),

4. 12365723 - Human plasma-derived IGG preparation enriched in anti-parvo B19 natural IGGS (2025-07-22),

5. 11891431 - Removal of serine proteases by treatment with finely divided silicon dioxide (2024-02-06),

6. 11242380 - Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use (2022-02-08),

7. 11136350 - Method to produce an immunoglobulin preparation with improved yield (2021-10-05),

8. 10875906 - Removal of serine proteases by treatment with finely divided silicon dioxide (2020-12-29),

9. 10738107 - Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural iggs (2020-08-11),

10. 10208106 - Removal of serine proteases by treatment with finely divided silicon dioxide (2019-02-19),

11. 10183976 - Method for producing factor H from a plasma precipitation fraction (2019-01-22),

12. 10125189 - Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use (2018-11-13),

13. 9896501 - Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural IgGs (2018-02-20),

14. 9855331 - Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH (2018-01-02),

15. 9783792 - Purification of butyrylcholinesterase using membrane adsorption (2017-10-10),

Title: Innovations and Contributions of Wolfgang Teschner

Introduction

Wolfgang Teschner is a prominent inventor based in Vienna, Austria, known for his significant contributions to the field of biomedicine through his extensive work on plasma-derived proteins. With a remarkable portfolio of 31 patents, Teschner has made impactful advancements that address critical healthcare challenges.

Latest Patents

Two of Wolfgang Teschner's latest patents showcase his innovative approaches to enhancing medical treatments. The first patent focuses on the "Removal of serine proteases by treatment with finely divided silicon dioxide," which provides novel methods for reducing serine protease and/or serine protease zymogen content in plasma-derived protein compositions. This invention includes aqueous and lyophilized compositions aimed at improving patient safety and efficacy. Furthermore, it outlines methods for treating, managing, and preventing diseases through the administration of modified protein compositions.

The second notable patent, "Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use," presents a new and improved technique for preparing immunoglobulin compositions from pooled plasma for subcutaneous injections. This patent describes a concentrated composition of 20% or more immunoglobulin, enhancing the delivery and effectiveness of treatments utilizing these crucial proteins.

Career Highlights

Throughout his career, Wolfgang Teschner has worked with notable organizations, including Baxalta GmbH and Baxter International Inc. These companies have provided a platform for Teschner's research and development efforts, allowing him to lead innovative projects that significantly contribute to the field of immunology and therapeutic applications.

Collaborations

Collaboration has been an essential aspect of Teschner's work. He has partnered and brainstormed with talented professionals such as Hans-Peter Schwarz and Azra Pljevljakovic. Together, they have contributed to the advancement of biopharmaceutical solutions and the improvement of healthcare treatments.

Conclusion

Wolfgang Teschner's extensive patent portfolio and his pioneering work in the biomedical field underscore his role as a leading inventor. Through his innovative patents and collaborations, Teschner continues to make substantial contributions to healthcare, enhancing the effectiveness of treatments available to patients worldwide.

Profile summary based on public USPTO records.